Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.

But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.

A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.

First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.

The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.

The ESMO presidential session will feature data from Destiny-Breast05 and 11.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

So who else could be interested in the oestrogen degrader?